Clinical Trial

Bone Marrow Protective Effect of Trilaciclib in Postoperative CCRT for LA-HNSCC

Study acronym: CCRT，LA-HNSCC
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 31, 2024 (before its estimated September 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the efficacy and safety of trilaciclib combined with standard treatment project as an adjuvant treatment for Head and neck cancer after surgery
Trial Details
NCT Number NCT06752798
Lead Sponsor Hunan Cancer Hospital
Conditions Head and Neck Cancer Squamous Cell Carcinoma
Enrollment 30 participants
Start Date 2024-12-30
Primary Completion 2025-09-30 (estimated)
Study Completion 2025-12-30 (estimated)
Updated on ClinicalTrials.gov 2024-12-31